Clarity Pharmaceuticals listed on the ASX (CU6) on 24 August 2021, raising $92M from the market and achieving a $360M market cap.
Clarity Pharmaceuticals
Manufacturer
Series A or Pre-seed or Seed (TBA)
(TBA)+ employees, $(TBA)M ARRSuccess Stories
Showcasing the innovative companies we're proud to support on their growth journey
Portfolio Companies
Jobs Created
Still Operating
Featured Companies
A selection of innovative companies we’ve invested in across various sectors
Success Stories
Clarity Pharmaceuticals
Manufacturer
Clarity Pharmaceuticals listed on the ASX (CU6) on 24 August 2021, raising $92M from the market and achieving a $360M market cap.
Clarity is the developer and manufacturer of a range of radiopharmaceutical “theranostic” products to image and treat cancers in adults and children.
Sydney Angels members first invested in Clarity in 2012 and participated in early follow-on rounds. First round investors enjoyed returns of 50x at IPO, an IRR of 46% p.a., and considerably higher if they held their shares through 2024.
50x
Revenue Growth(TBA)
Team Members$92M
Series A Raised(TBA)K+
Active Users
Revenue Growth(TBA)
Team Members$92M
Series A Raised(TBA)K+
Active Users